Daratumumab 400mg/20ml solution for infusion vials
NHS hospitals in England used £23,220,720 of indicative cost of Daratumumab 400mg/20ml solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 31.1% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Daratumumab 400mg/20ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Daratumumab 400mg/20ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Univ Hpl B/Ham Nhs Foundation Trust | £15,390,000 |
| The Clatterbridge Cancer Centre Nhs Ft | £6,642,000 |
| Southend Univ Hosp Nhs Foundation Trust | £171,360 |
| Imperial College Healthcare Nhs Trust | £164,160 |
| The Royal Marsden Nhs Foundation Trust | £146,880 |
| University College London Foundation Tr | £141,120 |
| United Lincolnshire Hospitals Nhs Trust | £116,640 |
| University Hospital Southampton Nhs Ft | £100,800 |
| Univ Hpls Bristol Nhs Foundation Trust | £80,640 |
| Barts Health Nhs Trust | £60,480 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.